HeartFlow: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 12, 2026, HeartFlow (NASDAQ:HTFL) raised its full-year revenue outlook to between $262 million and $264 million. The company is accelerating commercial adoption of its artificial intelligence diagnostic platform across cardiovascular care pathways. Expanding adoption and clinical trial milestones offer long-term investors a clear view of sustainable top-line growth. Three things management said on the call stand out. Revenue grew 57% year over year in the third quarter of 2026, driven by higher utilization of FFRct, an artificial intelligence tool measuring coronary artery blockage, and Plaque Analysis, a software program analyzing arterial vessel walls. Expanding sales of high-margin software helped lift non-GAAP gross margin, an adjusted measure excluding non-cash compensation, to 83.8%. Continue reading